Our focus is deeply rooted
in severe lung disease

KOL webinar on C21 for IPF with Prof. Toby Maher and Prof. Joanna Porter

Upcoming events

2021-12-16

DNB Healthcare Conference

2022-04-20 - 2022-04-21

Nordic Life Science days

Read more

Latest news

See all

Patient insights to shape development of a dCBT for IPF patients

Survey analysis of the psychological aspects of living with… Read More

Vicore’s ATTRACT study shows promise for novel drug C21 against COVID-19 in hospitalised patients

  We are pleased to announce that the results of our ATTRACT study… Read More

About us

Vicore is a clinical-stage pharmaceutical company focused on severe lung disease and related indications. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and COVID-19. VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2 receptor agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.?

The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

Fibrotic lung disease

Idiopathic pulmonary fibrosis (IPF) is the most common type of pulmonary fibrosis and is a severe and devastating disease with no known cause. It is characterized by a shrinking of the lungs due to the irreversible formation of fibrosis (i.e. scar tissue) causing stiffness, an irreversible loss of lung function and difficulty in breathing.

Our Vision

Vicore’s vision is to remove the pain and suffering caused by severe lung disease. As a company, we pride ourselves on our collaborative approach to science and are committed to working closely with the patient community, scientific experts and clinicians to find innovative solutions that meet their needs.